Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

This study is comparing two chemotherapy combinations for women with advanced triple-negative breast cancer (TNBC) — a type of breast cancer that lacks the three most common receptors, making it harder to treat with targeted therapies. Patients will receive either nab-paclitaxel plus carboplatin, or nab-paclitaxel plus capecitabine, to determine which combination works better. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have confirmed triple-negative breast cancer that is locally advanced or metastatic - You have received no more than one prior chemotherapy regimen for advanced disease - Your cancer is measurable on imaging - You are in reasonably good health (ECOG 0 or 1) and your liver, kidneys, and blood counts are within acceptable ranges - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have received more than one prior chemotherapy regimen for your advanced disease - Your organ function is significantly impaired Talk to your doctor to see if this trial is right for you.